Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Personalized Cancer Medicine

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_4475-11

Synonyms

Definition

Personalized medicine is defined as the application of the right treatment for the right patient, at the right dose and at the right time. Personalized medicine is therefore a model of the way medicine will evolve through the use of specific treatments and therapies best suited to an individual’s genotype and is driven by patient demand for safer and more effective medicines and therapies.

Characteristics

The concept of individualizing treatment is not new, and the study of hereditary influences on the response to drugs (pharmacogenetics) is reflected in the scientific literature from the 1960s. The number of articles published remained constant until 1996 when technical developments and new insights into the highly complex nature of many diseases resulted in the advent of pharmacogenomics. Pharmacogenomics is closely related to pharmacogenetics, but the emphasis is on the influence of a whole set or complement of genes on the response to...

Keywords

Chronic Myeloid Leukemia Gastrointestinal Stromal Tumor Personalized Medicine Multiple Endocrine Neoplasia Type Chronic Myeloid Leukemia Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Collins I, Workman P (2006) New approaches to molecular cancer therapeutics. Nat Chem Biol 2:689–700CrossRefPubMedGoogle Scholar
  2. Dietel M, Sers C (2006) Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch 448:744–755CrossRefPubMedGoogle Scholar
  3. Powis G (2006) Achieving personalized cancer medicine: trials and tribulations. J Invest Med 54:235–237CrossRefGoogle Scholar
  4. Sikora K (2007) Personalized medicine for cancer: from molecular signature to therapeutic choice. Adv Cancer Res 96:345–369CrossRefPubMedGoogle Scholar

See Also

  1. (2012) Avastin. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 323. doi: 10.1007/978-3-642-16483-5_6577Google Scholar
  2. (2012) Bioinformatics. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 403–404. doi: 10.1007/978-3-642-16483-5_631Google Scholar
  3. (2012) Biomarkers. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 408–409. doi: 10.1007/978-3-642-16483-5_6601Google Scholar
  4. (2012) Biopsy. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 415. doi: 10.1007/978-3-642-16483-5_644Google Scholar
  5. (2012) FISH. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 1415–1416. doi: 10.1007/978-3-642-16483-5_2197Google Scholar
  6. (2012) EGFR. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1211. doi: 10.1007/978-3-642-16483-5_1828Google Scholar
  7. (2012) Germline Mutation. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1544. doi: 10.1007/978-3-642-16483-5_2404Google Scholar
  8. (2012) GIST. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1548. doi: 10.1007/978-3-642-16483-5_2411Google Scholar
  9. (2012) Growth Factor. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 1607–1608. doi: 10.1007/978-3-642-16483-5_2520Google Scholar
  10. (2012) KIT. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 1945–1946. doi: 10.1007/978-3-642-16483-5_3228Google Scholar
  11. (2012) MYCN. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 2430–2431. doi: 10.1007/978-3-642-16483-5_3925Google Scholar
  12. (2012) Panitumumab. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2779. doi: 10.1007/978-3-642-16483-5_4362Google Scholar
  13. (2012) Personalized Medicine. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2828. doi: 10.1007/978-3-642-16483-5_4476Google Scholar
  14. (2012) Pharmacogenetics. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2840. doi: 10.1007/978-3-642-16483-5_4496Google Scholar
  15. (2012) Pharmacogenotype. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2844. doi: 10.1007/978-3-642-16483-5_4498Google Scholar
  16. (2012) Pharmacokinetics. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2845. doi: 10.1007/978-3-642-16483-5_4500Google Scholar
  17. (2012) Phenomics. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2855. doi: 10.1007/978-3-642-16483-5_4513Google Scholar
  18. (2012) Polymorphism. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 2954–2955. doi: 10.1007/978-3-642-16483-5_4673Google Scholar
  19. (2012) Targeted Therapy. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3610. doi: 10.1007/978-3-642-16483-5_5677Google Scholar
  20. (2012) Transcription. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3752. doi: 10.1007/978-3-642-16483-5_5899Google Scholar
  21. (2012) Wild-type. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3947. doi: 10.1007/978-3-642-16483-5_6247Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Harris Manchester CollegeUniversity of OxfordOxfordUK
  2. 2.NCI-Designated Cancer CenterSanford Burnham Prebys Medical Discovery InstituteLa JollaUSA